SOURCE: MediJane Holdings Inc.

July 15, 2014 08:05 ET

MediJane Holdings Completes Formulation of New Canna Liniment Product Line

LONGMONT, CO--(Marketwired - Jul 15, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or the "Company") is pleased to announce that it has completed the final formulation of its new Canna Liniment product line of topical analgesics. 

Canna Liniment is formulated for chronic pain and muscle soreness and will give pain sufferers another unique cannabinoid delivery system option. The new Canna Liniment formula is part of MediJane's continued penetration into the $45 billion pain management sector.

The Canna Liniment product is a Chinese-style liniment made with cannabis oil, wintergreen essential oil, and menthol all adding to its anti-inflammatory and analgesic properties. MediJane captures cannabis terpenes, which increase absorption and offer their own unique healing properties. 

"Being involved in sports and fitness for decades, I've used ordinary everyday liniments to help reduce pain and inflammation for many years. The American public is largely familiar with liniment products like Tiger Balm, Ben Gay, and Icy Hot. They're great products for what they do. Now we are able to provide relief to pain sufferers in a similar format but with the unique benefits of medical cannabis through our new and innovative formulation and Canna Liniment delivery system," stated Lewis "Spike" Humer, Chairman of MediJane. "The successful completion of the Canna Liniment formula allows us many more product development options, like roll-ons and a variety of balms, just to name a few. This once again represents another aspect of our constant evolution as a company and brand. We believe Canna Liniment will potentially provide numerous new revenue streams for the ultimate benefit of our shareholders." 

The Canna Liniment product line was developed under the guidance of MediJane Advisory Board member Pamela Clum. Prior to joining the MediJane Advisory Board in May 2014, she was the chief product formulator, developer, and marketer of the unique "CannaMist" brand of sublingual cannabinoid spray that is also now part of MediJane's portfolio of products exclusively licensed from Phoenix Bio Pharmaceuticals Corporation. Ms. Clum, who holds a Master's of Science in Botany from the University of Washington, formulated the first medicinal line of products containing cannabidiol (CBD) in the state of Colorado. 

About MediJane Holdings Inc. (MJMD)

MediJane Holdings Inc. (MJMD) is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, oral strips, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's products, including the innovative non-drowsy "Daytime Pain plus CBD" oral capsule, the CannaMist cannabinoid spray, and the MediStrip Relaxation oral strips, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's launch into the chronic pain management market. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.

For more information, visit www.medijane.co

Disclaimer/Safe Harbor: Some information in this MediJane press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MediJane's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in MediJane's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MediJane herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MediJane disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.

Contact Information